Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer

Article Category: Research Article

Published Online: Apr 07, 2022

Page range: 185 - 197

Received: Sep 26, 2021

Accepted: Jan 28, 2022

DOI: https://doi.org/10.2478/raon-2022-0012

Keywords

vactosertib, transforming growth factor-β (TGF-β), radiotherapy, epithelial-to-mesenchymal transition, cancer stem cell, breast cancer

© 2022 Jiwon Choi, Jiyoung Park, Ilyoung Cho, Yhunyhong Sheen, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.